Increased Blood-brain Barrier Permeability and Altered Tight Junctions in Experimental Diabetes in the Rat: Contribution of Hyperglycaemia and Matrix Metalloproteinases

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2006 Dec 5

PMID 17143608

Citations 147

Authors

B T Hawkins

T F Lundeen

K M Norwood

H L Brooks

R D Egleton

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Although diabetes mellitus is associated with peripheral microvascular complications and increased risk of neurological events, the mechanisms by which diabetes disrupts the blood-brain barrier (BBB) are not known. Matrix metalloproteinase (MMP) activity is increased in diabetic patients, is associated with degradation of tight junction proteins, and is a known mediator of BBB compromise. We hypothesise that diabetes leads to compromise of BBB tight junctions via stimulation of MMP activity.

Materials And Methods: Diabetes was induced in the rat with streptozotocin. At 14 days after injection, BBB function was assessed by in situ brain perfusion. Tight junction proteins were assessed by immunoblot and immunofluorescence. Plasma MMP activity was quantified by fluorometric gelatinase assay and gel zymography.

Results: In streptozotocin-treated animals, permeability to [(14)C]sucrose increased concurrently with decreased production of BBB tight junction proteins occludin (also known as OCLN) and zona occludens 1 (ZO-1, also known as tight junction protein 1 or TJP1). Insulin treatment, begun on day 7, normalised blood glucose levels and attenuated BBB hyperpermeability to [(14)C]sucrose. Neither acute hyperglycaemia in naive animals nor acute normalisation of blood glucose in streptozotocin-treated animals altered BBB permeability to [(14)C]sucrose. Plasma MMP activity was increased in streptozotocin-treated animals.

Conclusions/interpretation: These data indicate that diabetes increases BBB permeability via a loss of tight junction proteins, and that increased BBB permeability in diabetes does not result from hyperglycaemia alone. Increased plasma MMP activity is implicated in degradation of BBB tight junction proteins and increased BBB permeability in diabetes. Peripheral MMP activity may present a novel target for protection of the BBB and prevention of neurological complications in diabetes.

Citing Articles

Effects of Resveratrol on Redox Status, Jejunal Injury, and Mitochondrial Function in Intrauterine Growth-Retarded Weaned Piglets.

Cheng K, Yao J, Song Z, Huang J, Zhao H, Yang R Animals (Basel). 2025; 15(3).

PMID: 39943059 PMC: 11815716. DOI: 10.3390/ani15030290.

Review of Associations of Diabetes and Insulin Resistance With Brain Health in Three Harmonised Cohort Studies of Ageing and Dementia.

Biswas R, Capuano A, Mehta R, Barnes L, Bennett D, Arvanitakis Z Diabetes Metab Res Rev. 2025; 41(1):e70032.

PMID: 39873127 PMC: 11774135. DOI: 10.1002/dmrr.70032.

Zi Shen Wan Fang repaired blood-brain barrier integrity in diabetic cognitive impairment mice via preventing cerebrovascular cells senescence.

Yin Q, Yang G, Su R, Bu J, Li Y, Zhang H Chin Med. 2024; 19(1):169.

PMID: 39696612 PMC: 11657355. DOI: 10.1186/s13020-024-01041-6.

disrupts and reduces endothelial tight junction protein zonula occludens-1 in association with inflammasome activation.

Velatooru L, Arroyave E, Rippee-Brooks M, Burch M, Yang E, Zhu B Infect Immun. 2024; 93(1):e0046824.

PMID: 39679710 PMC: 11784141. DOI: 10.1128/iai.00468-24.

Regulation of the blood-brain barrier function by peripheral cues in health and disease.

Devraj K, Kulkarni O, Liebner S Metab Brain Dis. 2024; 40(1):61.

PMID: 39671124 PMC: 11645320. DOI: 10.1007/s11011-024-01468-8.

References

Nomura S, Yoshimura K, Akiyama N, Mikamo A, Furutani A, Aoki H . HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur Surg Res. 2006; 37(6):370-8. DOI: 10.1159/000090339. View

Williams S, Abbruscato T, Hruby V, Davis T . Passage of a delta-opioid receptor selective enkephalin, [D-penicillamine2,5] enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J Neurochem. 1996; 66(3):1289-99. DOI: 10.1046/j.1471-4159.1996.66031289.x. View

Yamagishi S, Imaizumi T . Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005; 11(18):2279-99. DOI: 10.2174/1381612054367300. View

Jacqueminet S, Ben Abdesselam O, Chapman M, Nicolay N, Foglietti M, Grimaldi A . Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta. 2006; 367(1-2):103-7. DOI: 10.1016/j.cca.2005.11.029. View

Mun-Bryce S, Rosenberg G . Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol. 1998; 274(5):R1203-11. DOI: 10.1152/ajpregu.1998.274.5.R1203. View

Signorelli S, Malaponte G, Libra M, Di Pino L, Celotta G, Bevelacqua V . Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med. 2005; 10(1):1-6. DOI: 10.1191/1358863x05vm582oa. View

LIKE A, Rossini A . Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976; 193(4251):415-7. DOI: 10.1126/science.180605. View

Huber J, Hau V, Borg L, Campos C, Egleton R, Davis T . Blood-brain barrier tight junctions are altered during a 72-h exposure to lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol. 2002; 283(4):H1531-7. DOI: 10.1152/ajpheart.00027.2002. View

Ristow M . Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl). 2004; 82(8):510-29. DOI: 10.1007/s00109-004-0552-1. View

10.

Dai J, Vrensen G, Schlingemann R . Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res. 2002; 954(2):311-6. DOI: 10.1016/s0006-8993(02)03294-8. View

11.

Haffner S, Stern M, Hazuda H, Mitchell B, PATTERSON J . Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA. 1990; 263(21):2893-8. DOI: 10.1001/jama.263.21.2893. View

12.

Giebel S, Menicucci G, McGuire P, Das A . Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005; 85(5):597-607. DOI: 10.1038/labinvest.3700251. View

13.

Hovsepyan M, Haas M, Boyajyan A, Guevorkyan A, Mamikonyan A, Myers S . Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus. Neurosci Lett. 2004; 369(3):224-7. DOI: 10.1016/j.neulet.2004.07.071. View

14.

Willis C, Leach L, Clarke G, Nolan C, Ray D . Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia. 2004; 48(1):1-13. DOI: 10.1002/glia.20049. View

15.

Maepea O, Karlsson C, Alm A . Blood-ocular and blood-brain barrier function in streptozocin-induced diabetes in rats. Arch Ophthalmol. 1984; 102(9):1366-9. DOI: 10.1001/archopht.1984.01040031108035. View

16.

Banks W, Jaspan J, Kastin A . Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin. Peptides. 1997; 18(10):1577-84. DOI: 10.1016/s0196-9781(97)00238-6. View

17.

Rosenberg G, Estrada E, Dencoff J . Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998; 29(10):2189-95. DOI: 10.1161/01.str.29.10.2189. View

18.

Harkness K, Adamson P, Sussman J, DAVIES-JONES G, Greenwood J, Woodroofe M . Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain. 2000; 123 ( Pt 4):698-709. DOI: 10.1093/brain/123.4.698. View

19.

Couture R, Harrisson M, Vianna R, Cloutier F . Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001; 429(1-3):161-76. DOI: 10.1016/s0014-2999(01)01318-8. View

20.

Lorenzi M, Healy D, Hawkins R, Printz J, Printz M . Studies on the permeability of the blood-brain barrier in experimental diabetes. Diabetologia. 1986; 29(1):58-62. DOI: 10.1007/BF02427282. View